Skip to main
TMDX

TMDX Stock Forecast & Price Target

TMDX Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 27%
Hold 36%
Sell 0%
Strong Sell 0%

Bulls say

TransMedics Group is poised to continue its rapid growth in the medical technology industry, driven by strong third quarter results and multiple growth initiatives in the pipeline. However, caution should be exercised due to historical seasonality patterns and potential challenges such as competition, regulatory delays, and the need for reimbursement coverage. The success of their main product, OCS Liver, in the US liver transplant market bodes well for future revenue growth.

Bears say

TransMedics Group is heavily reliant on its OCS technology and the successful commercialization of its products. However, with current management's cautious approach to expanding infrastructure and potential challenges in the lung market, there are concerns about the company's ability to scale and achieve profitable growth. In addition, competition in the market and potential disruptions from CMS' OPO modernization initiatives could negatively impact market growth for organ transplant therapies. Financially, the company has had weak gross margin and relatively high expenses, which could affect its profitability and limit its ability to invest in R&D for new products and technologies.

TMDX has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 27% recommend Buy, 36% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Transmedics Group Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Transmedics Group Inc (TMDX) Forecast

Analysts have given TMDX a Buy based on their latest research and market trends.

According to 11 analysts, TMDX has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $118.27, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $118.27, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Transmedics Group Inc (TMDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.